News

FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
Moderna falls on doubts over new CDC panel's backing of RSV vaccine
Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...
FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18 ...
BioPharma Dive1d
Moderna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...
Moderna RSV Vaccine Gets Expanded FDA Approval, Company Says
Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...
STAT1d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
FDA expands Moderna's RSV vaccine approval to at-risk adults
The U.S. Food and Drug Administration has approved Moderna’s (MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 ...
EconoTimes1d
FDA Expands Moderna’s RSV Vaccine Use to At-Risk Adults Aged 18–59
The U.S. Food and Drug Administration (FDA) has expanded the use of Modernas (NASDAQ:MRNA) RSV vaccine, mRESVIA, to adults ...